Dafinchi AI

LFST

Healthcare

Management is confident in achieving mid-teens revenue growth and expanding margins into the future.
Long-term, the company targets 15% to 20% EBITDA margins through center margin expansion, rate growth, and operating leverage.
Margin expansion in 2025 was driven by operational efficiencies despite payer dynamic challenges.
The growth algorithm includes increasing visit volumes, rate improvements, and leveraging G&A efficiencies for sustained margin growth.

SKIN

Healthcare

Adjusted EBITDA was $13.9 million, above expectations, supported by disciplined cost control and operational improvements.
Consumables sales totaled $55.8 million, up 0.8% year-over-year, with growth in Americas and EMEA offset by declines in APAC.
Device sales declined 36.5% year-over-year due to macroeconomic headwinds and transition in China to a distributor model.
GAAP gross margin improved significantly to 62.8% from 45.2% in the prior year, with adjusted gross margin at 65.9%.
Operating expenses decreased by 17.8%, with selling and marketing expenses down 24.2% and G&A expenses down 12.6%.
Q2 2025 revenue was $78.2 million, exceeding guidance and driven by consumables revenue growth and margin expansion.

Earnings Feed